BAAM
TGTX icon

Baker Avenue Asset Management’s TG Therapeutics TGTX Stock Holding History

Baker Avenue Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-93
Closed -$777 – 1375
2023
Q3 		$777 Hold
93
– – ﹤0.01% 1334
2023
Q2 		$2.31K Hold
93
– – ﹤0.01% 959
2023
Q1 		$1.4K Hold
93
– – ﹤0.01% 1082
2022
Q4 		$1.1K Buy
+93
New +$675 ﹤0.01% 1068

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Baker Avenue Asset Management's TGTX Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of TG Therapeutics (TGTX) in Q4 2023, closing a stake of 93 shares — an estimated $777 sold.

Baker Avenue Asset Management first reported a position in TGTX in Q4 2022 and held it in 4 quarters. The position peaked at $2.31K in Q2 2023. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining TG Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 93 TG Therapeutics shares in Q4 2023, an estimated $777.
  • Baker Avenue Asset Management first reported a position in TG Therapeutics in Q4 2022 and held it in 4 quarters.
  • Baker Avenue Asset Management's TG Therapeutics position peaked at $2.31K in Q2 2023.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.